Research programme - T-cell based cancer therapeutics - Eureka Therapeutics

Drug Profile

Research programme - T-cell based cancer therapeutics - Eureka Therapeutics

Alternative Names: ET 1402; ET 1402L1; ET 1501; ET 1502; ET 1504; ET 190; ET190L1; ET190L1-ARTEMIS™; ET190L1-ARTEMIS™ T-cell therapy

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eureka Therapeutics
  • Class Antibodies; Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Immunomodulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Liver cancer
  • Research Cervical cancer; Head and neck cancer; Lung cancer; Prostate cancer

Most Recent Events

  • 27 Nov 2017 Eureka Therapeutics plans a phase I trial for ET 190L1-ARTEMIS™ T-cells in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia (Second-line or greater therapy) in the first quarter of 2018
  • 27 Nov 2017 The US FDA approved an IND application for a phase I trial of ET 190L1-ARTEMIS™ T-cells in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia (Second-line or greater therapy)
  • 03 Dec 2016 Pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top